Doctors’ Adherence to the Guidelines on the Oral Anticoagulants Usage
Abstract
Aim. To study doctors’ knowledge of the clinical guidelines on the use of oral anticoagulants and identify the reasons for poor adherence.
Material and methods. The results of the 218 questionnaires completed by the doctors trained in the 2018-2019 were analyzed. The questionnaire included 12 items regarding the main aspects of oral anticoagulants use. 71.6% of respondents were cardiologists, 18.8% were therapists (including general practitioners) and 9.6% were representatives of other specialties.
Results. The obtained data show that therapists are worse than cardiologists aware of indications for oral anticoagulants in atrial fibrillation, and do not always correctly assess the risk of thromboembolism. Only 24.4% of therapists consider prescribing rivaroxaban in a dose of 2.5 mg 2 times a day to a patient suffering from myocardial infarction with an ST segment elevation on the electrocardiogram. One third of therapists either do not know or do not support current recommendations regarding oral anticoagulants use in paroxysmal atrial fibrillation. 65.3% cardiologists are inclined to start anticoagulant therapy only in patients at high risk for thromboembolism, while 36.6% therapists are ready to start such treatment even at moderate risk. Respondents' answers to the questionnaire demonstrate their great alertness regarding possible bleeding. Overestimation of the bleeding risk is more often among therapists than cardiologists (44.9% and 17.1%, respectively). More than one third of therapists (36.6%) are ready to recommend a reduced dose of oral anticoagulant to patients without clear reasons. Fear of bleeding has a greater influence on the decision to prescribe an anticoagulant and the choice of treatment regimen for atrial fibrillation than the desire to effectively prevent thromboembolism.
Conclusion. The results of the survey show that the doctors’ adherence to the clinical guidelines’ basic principles of the use of oral anticoagulants among cardiologists is higher than that of therapists. Wherein, even among cardiologists it cannot be considered sufficient. The lack of doctors’ awareness about the identification, assessment, and modification of risk factors for bleeding was revealed.
About the Authors
N. B. Perepech
Saint-Petersburg State University
Russian Federation
Russian Federation
Nikita B. Perepech – MD, PhD, Professor, Head of Clinical, Research and Education Center “Cardiology”
Universitetskaya nab. 7-9, St. Petersburg, 199034
I. E. Mikhailova
Saint-Petersburg State University
Russian Federation
Russian Federation
Irina E. Mikhailova – MD, PhD, Senior Researcher, Clinical, Research and Education Center “Cardiology”
Universitetskaya nab. 7-9, St. Petersburg, 199034
A. V. Tregubov
Saint-Petersburg State University
Russian Federation
Russian Federation
Aleksey V. Tregubov – MD, Researcher, Clinical, Research and Education Center “Cardiology”
Universitetskaya nab. 7-9, St. Petersburg, 199034
References
1. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;00:1-66. DOI:10.1093/eurheartj/ehx393.
2. Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017;00:1-48. DOI:10.1093/eurheartj/ehx419.
3. Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. DOI:10.1093/eurheartj/ehy136.
4. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;00:1-71. DOI:10.1093/eurheartj/ehz425.
5. Konstantinides S.V., Meyer G., Becattini C., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed collaboration with the European Respiratory Society (ERS). The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;00:1-61. DOI:10.1093/eurheartj/ehz405.
6. Reshetko O.V., Sokolov A.V., Furman N.V. Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(1):83-96 (In Russ.) DOI:10.24411/2588-0519-2018-10066.
7. Ruiz Ortiz M., Muñiz J., Raña Míguez P., et al. Inappropriate doses of direct oral anticoagulants in realworld clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577-83. DOI:10.1093/europace/eux316.
8. Chernov A.A., Kleymenova E.V., Sychev D.A., et al. Physician’s Adherence to Clinical Guidelines for inHospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501-8 (In Russ.) DOI:10.20996/1819-6446-2018-14-4-501-508.
9. Sato T., Aizawa Y., Fuse K., et al. Th e Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280-8. DOI:10.1016/j.jstrokecerebrovasdis.2018.07.028.
Review
For citations:
Perepech N.B., Mikhailova I.E., Tregubov A.V. Doctors’ Adherence to the Guidelines on the Oral Anticoagulants Usage. Rational Pharmacotherapy in Cardiology. 2020;16(5):706-712. (In Russ.) https://doi.org/10.20996/1819-6446-2020-10-15
Views: 306
Email this article 